1 / 3

Refractory Glaucoma Treatment Market to Proliferate at Double-Digit CAGR during the Forecast Period 2018-2026

Globally, Glaucoma is on rise. According to the Glaucoma research Foundation, Glaucoma is the leading cause of irreversible blindness globally.

RUSHIKESH
Download Presentation

Refractory Glaucoma Treatment Market to Proliferate at Double-Digit CAGR during the Forecast Period 2018-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Refractory Glaucoma Treatment Market to Proliferate at Double- Digit CAGR during the Forecast Period 2018-2026 Refractory Glaucoma Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 Refractory Glaucoma Treatment Market Globally, Glaucoma is on rise. According to the Glaucoma research Foundation, Glaucoma is the leading cause of irreversible blindness globally. Nearly 10% of the glaucoma patients who receive proper treatment still experience a loss of vision. Around 64.3 million people were estimated to be having glaucoma globally in 2013. Furthermore, according to the American Academy of Ophthalmology, the current prevalence is high in Africa, and Latin America. Patients who fail to respond to medications, undergo trabeculectomy surgery. However, few patients do not get completely relieved from glaucoma even after trabeculectomy surgery. Therefore, novel treatment options are required to be introduced for providing relief to

  2. such patients. Reducing intra-ocular pressure is the most important long term medical need of refractory glaucoma patients. Download PDF Brochure or Get Sample Copy @https://www.coherentmarketinsights.com/insight/request-pdf/71 Refractory Glaucoma Treatment Options The global refractory glaucoma treatment market can be characterized based on the treatment options and devices available in the market. Ahmed Glaucoma Valve from New World Medical Inc., is a good treatment option available since 1993 for refractory glaucoma. This device also has applications in primary open angle glaucoma unresponsive to medication, neovascular glaucoma, and congenital or infantile glaucoma. Various studies have refected the positive outcomes of using Ahmed Glaucoma Valve in refractory glaucoma both in pediatrics and adults. Therefore, this device is in very high demand and usage globally. Alternate option like CyPass Micro-Stent from Transcend Medical showed impressive results in patients with primary open-angle glaucoma. CyPass is a micro-invasive surgery which according to the FDA guidelines needs to be performed in combination with cataract surgery. This is restricting the wider acceptance among patients due to increased cost. Clinical trials of Xen System showed positive results with 44% reduction in eye pressure and 65% reduction in IOP medications in one year period. The Xen gel stent form Allergan reduces IOP with a permanent implant that becomes fexible, allowing doctors to use IOP reduction therapies event after the Xen implantation. Allergan received U.S. FDA approval for Xen Gel stent in November 2016. The company plans to launch the Xen Gel stent in the U.S. market, for refractory glaucoma treatment, in early 2017. The Xen system has already received CE mark and has distributed more than 10,500 stents globally. Moreover, the new surgical system is also licensed for use in Canada, Switzerland, and Turkey.

  3. Browse Detail Report @https://www.coherentmarketinsights.com/insight/request- customization/71 Iridex Corporation, a global provider of innovative laser systems, device and consumables in ophthalmology announced at the European Glaucoma Society held in June 2016 about the positive results of its MicroPulse P3 (MP3) device. The device powered with MicroPulse laser technology showed long term benefts for patients with refractory glaucoma. Few detailed studies with successful outcomes could lead global acceptance of this technology in future. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting frm ofering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

More Related